Deep Freeze: Innovations in Lyophilization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Deep Freeze: Innovations in Lyophilization
By reducing cycle time and implementing quality-by-design inspired engineering, advanced lyophilization systems are driving the industry toward greater efficiency and control.


Pharmaceutical Technology
Volume 33, Issue 4, pp. 36-42

Controlled freezing

One of the fundamental problems during freezing is that it often creates heterogeneous ice-crystal structures among the vials within a batch as well as among different batches. "It is a problem that has persisted and assumed to be inherent in freezing," says Robert Sever, Group Leader of research and development at Praxair (Chicago Technical Center, Burr Ridge, IL). The problem is that the vials do not all freeze at the same time nor at their expected freezing point.

For an aqueous solution, the freezing point is approximately 0 C. In a pharmaceutical environment, however, these containers will cool well below their freezing point (subcooling), to perhaps 20 or 30 below 0 C, before they will actually start to form ice (nucleation). These first few molecules are critical for obtaining crystal growth. In traditional lyophilization, nucleation temperatures range widely and are significantly below the thermodynamic freezing point. This variation is a result of pharmaceutical cleanroom environments where there is a lack of particulate contamination that helps ice nuclei form. As a result nucleation doesn't occur very easily and occurs only at very cold and highly variable temperatures. The freezing process is therefore random because the exact nucleation temperature for an individual vial cannot be predicted.

The nucleation temperature dictates many of the structural characteristics of ice. "The main problem that comes from not having control over this phenomenon, is that you have different ice structures in each vial, and some of these ice structures turn out to be very hindering when it comes to subsequent processing," says Sever. Vials that nucleate at a very cold temperature produce very dense ice structures, which impede subsequent sublimation in the drying steps and lead to very long drying times. "You may have some vials in a batch that have nucleated at warmer temperatures and are able to dry more quickly, but you ultimately have to run your freeze-drying cycle for your worst-case vials, which are those that have nucleated at very cold temperatures."

Dense ice structures also tend to negatively affect yield, depending on the type of structure that is created. Ice structures with large surface areas have the potential to damage active ingredients. Sensitive therapeutics such as proteins can aggregate or denature on these ice surfaces and may be damaged in subsequent processes.

After completion of the freezing step, it is possible to undergo an annealing stage to try to restructure the crystals. This strategy is practiced in the industry. However, as Sever points out, annealing often requires a substantially long time to complete. More important, annealing generally requires raising the product temperature above the critical collapse temperature of the material so that there is enough mobility in the system to allow the ice to restructure. Some consider this approach relatively risky for sensitive products. Annealing is an after-the-fact process, and it does not control the nucleation step.

A novel Praxair process technology uses inert gas pressure in a freeze dryer to induce nucleation during the freezing step. By precisely controlling this pressure, vials can be made to nucleate at a selected temperature. Having control over nucleation provides some control over stresses occurring during freezing and, in some cases, reduces aggregation events in proteins.

To date, Praxair has tested the method within 5m2 freeze-drying chambers and is expanding the process for 30 m2 units. It has used visual monitoring and various analytical methods to demonstrate the approach for a wide variety of model formulations.

Having greater control of this step may also lead to having the ability to tighten specifications, narrowing variability and increasing level of control, which is encouraged by FDA's quality-by-design initiative. "The process can deliver a much shorter drying cycle on the order of many hours or even days in some cases. However, the potential benefits of controlling nucleation go beyond controlling your ice structure for the sake of reducing drying time, as the preservation of the active ingredients is also strongly connected to the ice-crystal structure. This is a method for improving the product quality attributes and providing uniformity within a batch and among batches. And with the growing demand in protein therapeutics and increasingly sensitive biologicals, we are optimistic that there may be an important role for this technology."

Reference

1. A.A. Barresi et al., "In-line Control of the Lyophilization Process: A Gentle PAT Approach to Using Software Sensors," Internat. J. Refrigeration, http://www.sciencedirect.com/ (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here